Home
Investigations Index
DENSE-R-CHOP-14

DENSE-R-CHOP-14

Description:

No description specified

Health Atlas ID: 7WEY694PQ4-2

Projects: GLA - German Lymphoma Alliance

Help

Tree Split Graph

Export PNG

Click below to download a copy of the image

Download

Creators and Submitter

Creator

Marita Ziepert

Submitter

René Hänsel

Activity

Views: 597

Created: 16th May 2019 at 13:24

Last updated: 16th May 2019 at 13:24

Related items

Projects (1)
Studies (1)
Resources (2)
Publications (3)
Data files (5)
People (2)

GLA - German Lymphoma Alliance

B-cell lymphoma is the most frequent lymphoid neoplasia accounting for one third of all lymphomas. R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone) is the current treatment standard, leading to high cure rates especially in younger patients. Although the 3-year event-free survival is about 60% even for elderly patients between 60-80 years old, the remainder of patients eventually relapse and the majority die of their disease. The German Non-Hodgkin's Lymphoma Study
...

Programme: NHL

Public web page: https://www.dshnhl.org

Organisms: Homo sapiens

Human Diseases: non-Hodgkin lymphoma, B-cell lymphoma

DENSE-R-CHOP-14

GLA - German Lymphoma Alliance

All contributors

Marita Ziepert

No description specified

Person responsible: Marita Ziepert

Snapshots: No snapshots

Study type: Not specified

Investigation: DENSE-R-CHOP-14

Resources: DENSE-R-CHOP-14 trial data, DENSE-R-CHOP-14 trial metadata

Created: 16th May 2019 at 13:26, Last updated: 16th May 2019 at 13:40

DENSE-R-CHOP-14 trial metadata

GLA - German Lymphoma Alliance

All contributors

Marita Ziepert

Demographics, reference pathology diagnosis, Outcome (Event-free survival, Progression-free survival, Overall survival)

Submitter: René Hänsel

Resource type: Experimental Assay Type

Technology type: Technology Type

Snapshots: No snapshots

Investigation: DENSE-R-CHOP-14

Study: DENSE-R-CHOP-14

Organisms: No organisms

Human Diseases: diffuse large B-cell lymphoma

SOPs: No SOPs

Data files: DENSE-R-CHOP-14 trial data Metadata, DENSE-R-CHOP-14 trial data odm-Metadata

Created: 16th May 2019 at 13:32, Last updated: 16th May 2019 at 13:32

DENSE-R-CHOP-14 trial data

GLA - German Lymphoma Alliance

All contributors

Marita Ziepert

Demographics, reference pathology diagnosis, Outcome (Event-free survival, Progression-free survival, Overall survival)

Submitter: René Hänsel

Resource type: Experimental Assay Type

Technology type: Technology Type

Snapshots: No snapshots

Investigation: DENSE-R-CHOP-14

Study: DENSE-R-CHOP-14

Organisms: No organisms

Human Diseases: diffuse large B-cell lymphoma

SOPs: No SOPs

Data files: DENSE-R-CHOP-14 trial data ODM, DENSE-R-CHOP-14 trial data SPSS, DENSE-R-CHOP-14 trial data restricted CSV

Created: 15th May 2019 at 14:13, Last updated: 16th May 2019 at 13:27

CNS International Prognostic Index: A Risk Model for CNS Relapse in Patients With Diffuse Large B-Cell Lymphoma Treated With R-CHOP.

GLA - German Lymphoma Alliance

(Show All)

All contributors

Samira Zeynalova

Marita Ziepert

Markus Löffler

Abstract (Expand)

PURPOSE: To develop and validate a risk score for relapse in the CNS in patients with diffuse large B-cell lymphoma (DLBCL). PATIENTS AND METHODS: A total of 2,164 patients (18 to 80 years old) with … aggressive B-cell lymphomas (80% DLBCL) treated with rituximab and CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone)-like chemotherapy, who were enrolled in studies from the German High-Grade Non-Hodgkin Lymphoma Study Group and the MabThera International Trial, were analyzed for occurrence of relapse/progression in the CNS. The resulting risk model was validated in an independent data set of 1,597 patients with DLBCL identified in the British Columbia Cancer Agency Lymphoid Cancer database. RESULTS: The risk model consists of the International Prognostic Index (IPI) factors in addition to involvement of kidneys and/or adrenal glands (CNS-IPI). In a three-risk group model, the low-risk group (46% of all patients analyzed), the intermediate-risk group (41%), and the high-risk group (12%) showed 2-year rates of CNS disease of 0.6% (CI, 0% to 1.2%), 3.4% (CI, 2.2% to 4.4%), and 10.2% (CI, 6.3% to 14.1%), respectively. Patients from the validation British Columbia Cancer Agency data set showed similar rates of CNS disease for low-risk (0.8%; CI, 0.0% to 1.6%), intermediate-risk (3.9%; CI, 2.3% to 5.5%), and high-risk (12.0%; CI, 7.9% to 16.1%) groups. CONCLUSION: The CNS-IPI is a robust, highly reproducible tool that can be used to estimate the risk of CNS relapse/progression in patients with DLBCL treated with R-CHOP (rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone) chemotherapy. Close to 90% of patients with DLBCL belong to the low- and intermediate-risk groups and have a CNS relapse risk < 5%; they may be spared any diagnostic and therapeutic intervention. In contrast, those in the high-risk group have a > 10% risk of CNS relapse and should be considered for CNS-directed investigations and prophylactic interventions.

Authors: N. Schmitz, S. Zeynalova, M. Nickelsen, R. Kansara, D. Villa, L. H. Sehn, B. Glass, D. W. Scott, R. D. Gascoyne, J. M. Connors, M. Ziepert, M. Pfreundschuh, M. Loeffler, K. J. Savage

Date Published: 10th Sep 2016

Publication Type: Not specified

Human Diseases: diffuse large B-cell lymphoma

PubMed ID: 27382100

Citation: J Clin Oncol. 2016 Sep 10;34(26):3150-6. doi: 10.1200/JCO.2015.65.6520. Epub 2016 Jul 5.

Created: 17th Apr 2019 at 13:59, Last updated: 16th May 2019 at 15:09

Elevated serum free light chains do not predict outcome of elderly patients with aggressive CD20(+) B-cell lymphomas.

GLA - German Lymphoma Alliance

All contributors

Bettina Altmann

Marita Ziepert

Abstract

Not specified

Authors: M. Achenbach, J. T. Bittenbring, M. Ziepert, E. Regitz, G. Ott, A. Rosenwald, M. Pfreundschuh, B. Altmann, G. Held

Date Published: 1st Jul 2014

Publication Type: Not specified

Human Diseases: B-cell lymphoma

PubMed ID: 24974897

Citation: Br J Haematol. 2014 Nov;167(3):430-4. doi: 10.1111/bjh.13001. Epub 2014 Jun 27.

Created: 16th Apr 2019 at 15:02, Last updated: 16th May 2019 at 14:21

Optimization of rituximab for the treatment of DLBCL (I): dose-dense rituximab in the DENSE-R-CHOP-14 trial of the DSHNHL.

GLA - German Lymphoma Alliance

All contributors

Samira Zeynalova

Abstract (Expand)

BACKGROUND: To improve outcome of elderly patients with diffuse large B-cell lymphoma, dose-dense rituximab was evaluated in the prospective DENSE-R-CHOP-14 trial. PATIENTS AND METHODS: Rituximab (375 … mg/m(2)) was given on days 0, 1, 4, 8, 15, 22, 29, 43, 57, 71, 85, and 99 together with six CHOP-14 cycles. Results were to be compared with patients who had received the same chemotherapy in combination with eight 2-week applications of rituximab in RICOVER-60. RESULTS: One hundred twenty-four patients are assessable. Dose-dense rituximab resulted in considerably higher serum levels during the first 50 days of treatment, but rituximab exposure time was not prolonged. Grade 3 and 4 infections were exceptionally high in the first 20 patients without anti-infective prophylaxis, but decreased after introduction of prophylaxis with aciclovir and cotrimoxazole in the remaining 104 patients (from 13% to 6% per cycle and from 35% to 18% per patient; P = 0.007 and P = 0.125, respectively). Patients with international prognostic index = 3-5 had higher complete response/complete response unconfirmed rates (82% versus 68%; P = 0.033) than in the respective RICOVER-60 population, but this did not translate into better long-term outcome, even though male hazard was decreased (event-free survival: from 1.5 to 1.1; progression-free survival: from 1.7 to 1.1; overall survival: from 1.4 to 1.0). CONCLUSIONS: Dose-dense rituximab achieved higher rituximab serum levels, but was not more effective than eight 2-week applications in the historical control population, even though minor improvements in poor-prognosis and male patients cannot be excluded. The increased, though manageable toxicity, precludes its use in routine practice. Our results strongly support anti-infective prophylaxis with aciclovir and cotrimoxazole for all patients receiving R-CHOP.

Authors: N. Murawski, M. Pfreundschuh, S. Zeynalova, V. Poeschel, M. Hanel, G. Held, N. Schmitz, A. Viardot, C. Schmidt, M. Hallek, M. Witzens-Harig, L. Trumper, T. Rixecker, C. Zwick

Date Published: 15th Jun 2014

Publication Type: Not specified

Human Diseases: non-Hodgkin lymphoma, diffuse large B-cell lymphoma

PubMed ID: 24928834

Citation: Ann Oncol. 2014 Sep;25(9):1800-6. doi: 10.1093/annonc/mdu208. Epub 2014 Jun 13.

Created: 13th May 2019 at 11:31, Last updated: 13th May 2019 at 11:32